

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

NOV 1 7 2003

Applicants:

LACRAMPE, J. F. A. et al.

TECH CENTER 1600/2900

Serial No.:

10/075,876

Art Unit: 1624

Filed :

February 14, 2002

Examiner: BALASUBRAMANIAN, V.

Title

Non-Steroidal IL-5 Inhibitors, Processes and Intermediate For Their Preparation And Pharmaceutical Compositions Comprising Said Inhibitors

Commissioner for Patents Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §\$1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

11/12/2003 GWORDOF1 00000093 100750 10075876

01 FC:1806 180.00 DA

In accordance with §1.97(b), since this Information
Disclosure Statement is being filed either within three months
of the filing date of the above-identified national application
(other than a continued prosecution application under
\$1.53(d)), within three months of the date of entry into the
national stage of the above identified application as set forth
in \$1.491, or before the mailing date of a first Office Action
on the merits of the above-identified application, or before
the mailing date of a first Office Action after the filing of a
request for continued examination under \$1.114, no additional
fee is required.
In accordance with \$1.129(a), this Information
Disclosure Statement is being filed in connection with [] the
first or _second After Final Submission, therefore:
Statement in Accordance with \$1.97(e)
(attached); or
Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth
in §1.17(p).
- ca ca ca ca ca this Information
☐ In accordance with \$1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in §1.97(b) above but before the mailing date of either a Final
Action under \$1.113 or a Notice of Allowance under \$1.311, or
an action that otherwise closes prosecution and that it is
accompanied by one of:
Statement in Accordance with §1.97(e)
(attached); or

□ Please charge Deposit Account No. 10-0750/JAB
1694/AGK the fee of \$180.00 as set forth in
§1.17(p).
In accordance with \$1.97(d), this Information
Disclosure Statement is being filed after the mailing date of
either a Final Action under §1.113 or a Notice of Allowance
under \$1.311 but before the payment of the Issue Fee.
Applicant(s) hereby petition(s) for consideration of this
Information Disclosure Statement. Included are: Statement in
Accordance with \$1.97(e) as set forth below and the fee of
\$180.00 as set forth in \$1.17(p).
○ Copies of each of the references listed on the
attached Form PTO-1449 are enclosed herewith.
Copies of references listed on the attached Form PTO-
1449 are enclosed herewith EXCEPT THAT:
In view of the voluminous nature of references
[list as appropriate], and the likelihood that
these references are available to the Examiner,
copies are not enclosed herewith.
1.13 matical and not
If any of the foregoing publications are not
available to the Examiner, Applicant will
endeavor to supply copies at the Examiner's
request.
∏ There are no listed references which are not in the
English language.

The relevance of those listed references which are not in the English language is as follows:

Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

Attached are copies of office action(s) received in U.S.S.N. 10/049,038, which are listed on the attached Submission Under MPEP 609 D.

Attached are the following pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D: Published Application for U.S. Patent 2002/0010177; and Published Application for U.S. Patent 20020042416.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/JAB 1694-PCT/AGK. This form is submitted in triplicate.

Respectfully submitted,

Alana G. Kriegsman

Reg. No. 41747

Attorney for Applicants

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-1495 DATED: November 7, 2003



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

k Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

a collection of information unless it displays a	VAIIG CIVID CONSULTIGITIDES.
Application Number	10/075,876
Filing Date	February 14, 2002
First Named Inventor	Lacrampe, J. F. A.
Group Art Unit	1624
Examiner Name	Balasubramanian, V.
Attorney Docket Number	JAB 1694

	U.S. Patent Document			
Cite No. ¹	Kind Code ² Number (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
	US 4,631,278	Boeckx et al.	12-23-1986	
	US 2002/0010177	Freyne et al.	01-24-2002	
	US 2002/0042416	Freyne et al.	04-11-2002	ECFIVED
			_	NOV 1 7 2003
			TECH	CENTER 1600/290
		Cite No.1 Kind Code ² Number (if known) US 4,631,278 US 2002/0010177	Cite No.1 Kind Code ² Name of Patentee or Applicant of Cited Document US 4,631,278 Boeckx et al. US 2002/0010177 Freyne et al.	Cite No.1 Kind Code ² (if known) Name of Patentee or Applicant of Cited Document Date of Publication of Cited Document mm-dd-yyyy US 4,631,278 Boeckx et al. 12-23-1986 US 2002/0010177 Freyne et al. 01-24-2002 US 2002/0042416 Freyne et al. 04-11-2002

FOREIGN PATENT DOCUMENTS Date of Publication Pages, Columns, Lines, Foreign Patent Document of Cited Document where relevant Name of Patentee or passages or relevant Examiner Cite T⁶ mm-dd-yyyy Applicant of Cited Document figures appear Initials Number⁴ KindCode⁵ EP 0170316 В1 Janssen Pharmaceutica N.V. 05/30/1990 ΕP 0232932 В1 Janssen Pharnaceutica N.V. 01/02/1991

-Examiner-	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Alexandria, VA 22313.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

on Act of 1995, no persons are required to respond to Under the Pa

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a collection of information unless it displays a	valid OMB control number.
Application Number	10/075,876
Filing Date	February 14, 2002
First Named Inventor	Lacrampe, J. F. A.
Group Art Unit	1624
Examiner Name	Balasubramanian, V.
Attorney Docket Number	JAB 1694

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		WANG-LIN, Y., et al., "Synthesis of 1,4-bis(1,3,4-oxadiazol-2-yl)-2,5-dialkoxybenzene-	
	1	oligothiophene copolymers with different emissive colors: synthetically tuning the	
		photoluminescence of conjugated polymers." Chemical Comm. 1957, pages 1957-1958.	
		BUZAS, A., et al., CAPLUS Accession No. 1961:131401, Chemical Abstract, 1961 , Vol. 55, Abstract # 131,401.	
		PEET, N.P., et al., "Synthesis of a Novel Indolobenzodiazepine." <u>J. Heterocyclic Chem., 1983, pages 1355–1357, Vol. 20.</u>	
		CARR, M. W. et al., "Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant." ." Proc. Natl. Acad. Sci, 1994, 91, 3652-3656.	
	J T	BAGGIOLINI, M., et al., "CC chemokines in allergic inflammation, Immunology Today, 15(3), 127-133.	
	<u> </u>	TEO NOW	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
Examiner		Date Considered	2

Examiner		Date	
Signature	<u> </u>	 Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Alexandria, VA 22313.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Alexandria, VA 22313.

U.S. PATENT	DOCUMENTS	
Page 1 of 1	Attom y Dock t Numb r	JAB 1694
	Examiner Name	Balasubramanian, V.
SUBMISSION UNDER MPEP 609 D	Group Art Unit	1624
	First Named Inventor	Lacrampe, J. F. A.
	Filing Dat	February 14, 2002
	Application Number	10/075,876

			U.S. Patent Docum	nent	Pages, Columns, Lines,
Examiner Initials	Cite	Name of Patentee or Applicant of Cited Document	Number	Kind Code ² (if known)	where relevant passages or relevant figures appear
	 				
	 				
	 				
	1)=
	+-+				
	 				
		_			

		FUREIGI		DOCUMEN		1 = 4	
Examiner Initials	Cite	Name of Patentee or Applicant of Cited Document	Foreign Pa	atent Docum	ent KindCode ⁵	Pages, Columns, Lines, where relevant passages or relevant figures appear	τ°
· · · · · · · · · · · · · · · · · · ·				T			
	<u> </u>	OTHER PRIOR ART - N	ON PATEN	LITERATU	RE DOCUME	NTS	
		Include name of the author (in C	APITOL LI	ETTERS), t	itle of the art	icle (when appropriate),	T ²
Examiner 's	Cite No.1	title of the item (book, magazine volume-issue number(s	e, joumal, s s), publishe	erial, symp er, city and/	osium, catalo or country w	og, etc.), date, page(s), nere published	
Initials*		PCT International Search Report PCT/	ED00/07358	dated 01-25	-2001 which n	elates to U.S. Application	
		No. 10/075 876					
		Published Application for U.S. Patent MicroPatent® Family Lookup.					
		Office Action received in U.S.S.N. 10/0					
		Published Application for U.S. Patent 2	002004241	(A1), and a	MicroPatent®	Family Lookup.	<u> </u>
	 						
	ļ						

Examiner	Date
CABITILIE	المشيدين بقال
Signature	Considered
Organical	